The CASP6 Knockout KYSE-150 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human esophageal squamous cell carcinoma line KYSE-150, featuring targeted disruption of the CASP6 gene. This loss-of-function model abolishes caspase-6 expression, providing a powerful tool for dissecting apoptosis signaling and exploring non-apoptotic functions of the executioner caspase. The polyclonal nature ensures representation of diverse editing outcomes, suitable for studying population-level responses without clonal isolation.
KYSE-150 is a human esophageal squamous cell carcinoma cell line established from a well-differentiated invasive esophageal carcinoma, widely used as a model for esophageal cancer biology and drug response studies. The cell line retains key characteristics of esophageal cancer, including robust proliferation and invasive potential, making it ideal for investigating molecular mechanisms underlying tumor progression and drug resistance.
Encoded by CASP6, caspase-6 is an executioner caspase that functions downstream of initiator caspases caspase-8 and caspase-9 in the intrinsic and extrinsic apoptotic pathways, cleaving substrates lamin A/C and PARP to effect cellular demolition. It also contributes to neurodegeneration through processing of proteins implicated in Alzheimer??s and Huntington??s diseases. Within the caspase cascade, caspase-6 is activated by caspase-3 and regulated by interactions with XIAP and survivin. Disruption of CASP6 in KYSE-150 cells impairs proteolytic signaling downstream of CYCS/APAF1 apoptosome formation and death receptor engagement, where BID and BAX link mitochondrial outer membrane permeabilization to executioner caspase activation.
In the KYSE-150 esophageal carcinoma context, CASP6 knockout potentially confers resistance to intrinsic and extrinsic apoptotic stimuli, recapitulating a mechanism often observed in therapy-resistant cancers. The loss of this executioner caspase may enhance cell survival under genotoxic stress and contribute to oncogenic phenotypes, making this model valuable for studying apoptosis evasion in esophageal squamous cell carcinoma. It enables investigation of compensatory survival pathways and the non-apoptotic roles of caspase-6 in tumor progression, such as cytoskeletal remodeling or cell cycle regulation.
Researchers can employ these polyclonal knockout cells for mechanistic studies including caspase activity assays, Annexin V apoptosis detection, western blotting for substrate cleavage, and drug sensitivity testing to identify caspase-6-dependent therapeutics. The system is well-suited for high-content screening of pro-apoptotic agents and for interrogating interactions with key regulators such as caspase-8, caspase-9, and caspase-3. For further information, please contact Ascent Research.
